Liu Zhe, Lv Sha, Wang Shuang, Qu Sheng-Ming, Zhang Gui-Yun, Lin Yi-Tong, Yang Lei, Li Fu-Qiu
Department of Dermatology, The Second Hospital of Jilin University, Changchun 130041, Jilin Province, China.
World J Clin Cases. 2021 Oct 6;9(28):8579-8586. doi: 10.12998/wjcc.v9.i28.8579.
Infantile hemangiomas (IHs) are the most common childhood benign tumors, showing distinctive progression characteristics and outcomes. Due to the high demand for aesthetics among parents of IH babies, early intervention is critical in some cases. β-Adrenergic blockers and corticosteroids are first-line medications for IHs, while itraconazole, an antifungal medicine, has shown positive results in recent years.
In the present study, itraconazole was applied to treat two IH cases. The therapeutic course lasted 80-90 d, during which the visible lesion faded by more than 90%. Moreover, no obvious side effects were reported, and the compliance of the baby and parents was desirable.
Although these outcomes further support itraconazole as an effective therapeutic choice for IHs, large-scale clinical and basic studies are still warranted to improve further treatment.
婴儿血管瘤（IHs）是儿童期最常见的良性肿瘤，具有独特的进展特征和转归。由于患有IH的婴儿的父母对美观有很高要求，在某些情况下早期干预至关重要。β-肾上腺素能阻滞剂和皮质类固醇是治疗IHs的一线药物，而抗真菌药物伊曲康唑近年来已显示出积极效果。
在本研究中，应用伊曲康唑治疗2例IHs病例。疗程持续80 - 90天，在此期间可见病变消退超过90%。此外，未报告明显副作用，婴儿及家长的依从性良好。
尽管这些结果进一步支持伊曲康唑作为治疗IHs的有效治疗选择，但仍需要大规模的临床和基础研究来进一步改进治疗。
